BioMed Research International / 2016 / Article / Tab 3

Research Article

A Retrospective Observational Study to Assess Prescription Pattern in Patients with Type B Aortic Dissection and Treatment Outcome

Table 3

Prescribing patterns of nonoperated TBAD patients.

Medication (%) Before index dateAfter index date

-blockers15 (14.2)85 (80.2)
 Selective -blockers9 (8.5)71 (67.0)
  Atenolol3 (2.8)4 (3.8)
  Bisoprolol6 (5.7)68 (64.2)
 Nonselective -blockers4 (3.8)5 (4.7)
  Propranolol4 (3.8)5 (4.7)
- and -blockers5 (4.7)10 (9.4)
  Carvedilol4 (3.8)8 (7.6)
  Labetalol1 (1.0)2 (1.9)
ACEIs/ARBs22 (20.8)54 (50.9)
 ACEIs7 (6.6)7 (6.6)
  Captopril1 (0.9)1 (0.9)
  Fosinopril1 (0.9)1 (0.9)
  Imidapril0 (0)2 (1.9)
  Lisinopril0 (0)1 (0.9)
  Perindopril1 (0.9)1 (0.9)
  Quinapril2 (1.9)0 (0)
  Ramipril4 (3.8)2 (1.9)
 ARBs18 (17.0)49 (46.2)
  Candesartan4 (3.8)15 (14.2)
  Irbesartan7 (6.6)18 (17.0)
  Losartan1 (0.9)5 (4.7)
  Olmesartan6 (5.7)10 (9.4)
  Telmisartan1 (0.9)1 (0.9)
  Valsartan10 (9.4)27 (25.5)
CCBs 25 (23.6)94 (88.7)
 Dihydropyridine22 (20.8)92 (86.8)
  Amlodipine17 (16.0)62 (58.5)
  Felodipine3 (2.8)1 (0.9)
  Lercanidipine2 (1.9)5 (4.7)
  Nicardipine1 (0.9)17 (16.0)
 Nondihydropyridine5 (4.7)7 (6.6)
  Diltiazem4 (3.8)7 (6.6)
  Verapamil1 (0.9)0 (0)
Vasodilator14 (13.2)30 (28.3)
Diuretics16 (15.1)39 (36.8)
-blockers6 (5.7)26 (24.5)
Statins15 (14.2)49 (46.2)
 Atorvastatin12 (11.3)26 (24.5)
 Rosuvastatin5 (4.7)23 (21.7)
 Fluvastatin1 (1.0)4 (3.8)
 Pravastatin3 (2.8)5 (4.7)
Other lipid-lowering agents7 (6.6)14 (13.2)
Antiplatelet agents17 (16.0)39 (36.8)
 Aspirin13 (12.3)34 (32.1)
 Clopidogrel10 (9.4)13 (12.3)
 Dipyridamole4 (3.8)5 (4.7)
Warfarin2 (1.9)2 (1.9)
Antidiabetic agents6 (5.7)18 (17.0)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.